TauRx went big at the Clinical Trials on Alzheimer’s Disease (CTAD) annual meeting in San Francisco, insisting that its investigational anti-tau agent, hydromethylthionine mesylate (HMTM), exerted cognitive benefit and slowed brain atrophy in an ongoing phase 3 trial — despite a prior admission that a blinded study of the drug is virtually impossible.
Source: Drug Industry Daily